Report
EUR 13.82 For Business Accounts Only

ROHTO PHARMACEUTICAL sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of ROHTO PHARMACEUTICAL (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date November 16, 2021, the closing price was JPY 3,305.00 and its target price was estimated at JPY 3,061.68.
Underlying
Rohto Pharmaceutical Co. Ltd.

Rohto Pharmaceutical and its affiliates are mainly engaged in the manufacture and sale of pharmaceuticals and related products. Co.'s eye care products include eye drops, eyewash preparations, and contact lens products under the name of "Namida (Tear) Rohto Contact," "Rohto Dryaid," "ALGUARD Refreshing Eyewash" and "Rohto C Cube." Co.'s skincare products include dermal medicines, lip balms, hand cream, body cream, acne treatments, sunscreens, and other skin care products under the name of "Mentholatum." Co.'s internal medicines include gastrointestinal medicines, liquid gastrointestinal medicines, cold remedies, motion sickness drugs, Chinese herbal medicines and supplements.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch